42 results about "Growth factor receptor inhibitor" patented technology

Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I)and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).

The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of at least one target gene of hsa-miR-31 -3p (SEQ ID NO:1 ) miRNA in a sample of said patient, wherein said target gene of hsa-miR-31 -3p is selected from DBNDD2 and EPB41 L4B. The invention also relates to kits for measuring the expression of DBNDD2 and / or EPB41 L4B and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.

The present invention is directed to methods for the treatment of gefitinib and / or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and / or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and / or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

The invention relates to a compound containing a conjugated allene amide structure and a preparation method, a medicine composition and application thereof, in particular to a compound containing a conjugated allene amide structure shown in a formula (I), and a preparation method, a medicine composition and application thereof in preparation of an EGFR (epidermal growth factor receptor) inhibitoror a medicine for preventing and / or treating EGFR-related diseases, especially cancers. (The formula (I) is shown in the description.).

The invention discloses a cyclic adenosine monophosphate boric acid complex, a preparation method thereof, an anti-tumor drug and a neutron capture therapy boron agent. The cyclic adenosine monophosphate boric acid complex serves as a boron-containing compound, a boron-containing epidermal growth factor receptor inhibitor and a boron-containing nucleoside epidermal growth factor receptor inhibitor, cancer cells absorb the boron agent, propagation of the cancer cells needs a lot of nucleosides, so that the drug is enriched to sensitive targets such as cancer cell membranes, cancer cells are killed by the aid of neutron capture specificity, drug selectivity is widened, so that the killed efficiency of the cancer cells is greatly improved, and the cyclic adenosine monophosphate boric acid complex solves the problems that most boron agents in current neutron capture therapy only have single function, only the one-sided effect of selectively absorbing neutron energy to kill tumors is improved in neutron capture therapy, the killed efficiency of the cancer cells is low, and selectivity is poor.

The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.

The invention relates to the application of p-hydroxyphenylacetic acid in the prevention and / or treatment of cardiovascular diseases. The invention firstly finds that p-hydroxyphenylacetic acid has a better therapeutic effect on blood vessel and heart damage. For zebrafish interbody vessel (ISV) injury and inferior intestinal vein (SIV) growth induced by vascular endothelial cell growth factor receptor inhibitor (PTK787), p-hydroxyphenylacetic acid can significantly promote angiogenesis. increase in the number and length of blood vessels. For verapamil-induced zebrafish heart failure and terfenadine-induced arrhythmia, p-hydroxyphenylacetic acid has a significant protective effect on the heart, can significantly reduce cardiac dilation, relieve venous congestion and promote heart rate to normalize.